NCT01978236: Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites |
|
|
| Terminated | 2b | 6 | US, RoW | Dabrafenib 150 mg, Trametinib 2.0 mg | GlaxoSmithKline | Melanoma and Brain Metastases | 04/17 | 04/17 | | |
NCT01721603: Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets |
|
|
| Terminated | 2 | 2 | US | Dabrafenib, GSK2118436, Gamma Knife Radiosurgery, SRS, Stereotactic Radiosurgery, Trametinib, GSK1120212 | University of California, San Francisco, GlaxoSmithKline | BRAFV600E Melanoma Patients | 01/16 | 01/16 | | |
